New Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date").  In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, a

CAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum. Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Thursday, November 14, at 1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the

Reported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics  $21.7 Million in Cash at End of Third Quarter Expected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass., Nov. 7, 2024 /PRN

CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: October 7: H.C. Wainwright 8th Annual MASH Virtual Conference. Hyung Heon Kim, President and Chief Executive Officer, will present a company overview on Monday, October 7, at 11:00 am ET.Management will also be available for one-on-one meetings during the event. Individuals who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at https://hcwevents.

Data Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R)

CAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Tuesday, September 10, at 1:30 pm ET, during the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York. Management will also be available for one-on-one meetings during the event. Institutional investors who would like to listen to the Company's presentation or request a meeting can do so after registeri

Successfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warrants $27.9 Million in Cash at End of Second Quarter is Expected to Fund the Company Though Multiple Value-Creating Milestones, Into the Second Quarter of 2025. Assuming Positive Results From the DA-1726 Phase 1 MAD Study, the Company Anticipates That the Series A Warrants From the June Financing Could be Exercised in the First Half of 2025, Resulting in Gross Proceeds of $20 Million In Pre-Clinical Models, DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass and Lipid-Lowe

No Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SAD Part 1 Expected in the Third Quarter of 2024, and from the MAD Part 2 in the First Quarter of 2025 CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like pepti

Collaboration to Leverage ImmunoForge's ELP Platform Technology Which Can Increase the Half-Life of a Drug by up to 200 Times CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has signed a joint research agreement, together with Dong-A ST Co. Ltd. and ImmunoForge, to develop a long-acting, once-monthly, formulation of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), utilizing ImmunoForge's long-lasting half-life extension Elastin-Like Polyp

CAMBRIDGE, Mass., July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced the signing of an exclusive license agreement, providing MThera Pharma Co., Ltd. (MTHERA) with the rights to NB-01 for the treatment of painful diabetic neuropathy. The agreement allows MTHERA to conduct research and clinical trials, including, but not limited to, a potential Phase 3 clinical trial in the United States and South Korea, for the future commercialization of NB-01. Financial terms of the agreement were not disclosed. "Finalizing this agreement for NB-01 is an important miles

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

10-Q - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

DEF 14A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

10-Q - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

HC Wainwright & Co. reiterated coverage of NeuroBo Pharmaceuticals with a rating of Buy and set a new price target of $16.00 from $20.00 previously

https://s27.q4cdn.com/906368049/files/News/2024/Zacks_SCR_Research_07012024_NRBO_Bautz.pdf

The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Nanophase Technologies The Trade: Nanophase Technologies Corporation (NASDAQ:NANX) Chief Operating Officer Kevin Cureton bought a total of 11,675 shares at an average price of $1.49. To acquire these shares, it cost around $17,414. What's Happ

- Form4

 NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced pre-clinical data which indicates that DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), demonstrated superiority in weight loss, retention of lean body mass, and lipid-lowering effects compared to survodutide, in pre-clinical models. Tae-Hyoung Kim, Lead research scientist, Dong-A ST Research Center, will present the data today, in a poster at the American Diabetes Association (ADA) 84th Scientific Sessions, taking place June 21-24, in 

NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday. The Boston-based company announced preclinical data for its novel “G-Protein-Coupled Receptor 119 (GPR119) agonist,” known as DA-1241. The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S’s (NYSE:NVO) semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective effects compared to either treatment alone.  DA-1241 did not influence liver weight, the company said. In contrast, semaglutide reduced body weight by approximately 25% and improved hepatomegaly in GAN DIO-MASH mice with or without combination treatment.  Th

BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the year ended December 31, 2020 and provided a corporate strategic update. "In December 2020, we significantly expanded our clinical pipeline with the acquisition of ANA Therapeutics and the addition of lead drug candidate, ANA001, a proprietary oral niclosamide formulation, currently in a 60-patient Phase 2/3 trial as a treatment for moderate to severe COVID-19," stated Richard J. Kang, Ph.D., Pres

Dosed First Patient in the Single Ascending Dose Part 1 of the Phase 1 Clinical Trial of DA-1726 in Obesity, With Top-Line Data Readout Expected in the Third Quarter of 2024 Anticipate First Patient to be Dosed in the Multiple Ascending Dose Part 2 of the Phase 1 Clinical Trial of DA-1726 in the Third Quarter of 2024 Part 2 of the Phase 2a Trial of DA-1241 for the Treatment of MASH Underway After Enrollment of Part 1 Completed, With Data Expected in the Fourth Quarter of 2024 Cash of $16.0 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., May 9, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focus

Received First Site Institutional Review Board (IRB) Approval to Proceed With the Phase 1 Trial of DA-1726 in Obesity Phase 1 Trial of DA-1726 Expected to Dose First Patient in Second Quarter of 2024 Received Safety Review Committee (SRC) Approval Recommending That the Two-Part Phase 2a Trial of DA-1241 for the Treatment of MASH Continue Without Modification Data from the Phase 2a Trial of DA-1241 Expected in the Second Half of 2024 Cash of $22.4 Million, Expected to Fund the Company Into the Fourth Quarter of 2024 CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseas

CAMBRIDGE, Mass., March 4, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic diseases, today announced the appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective March 1, 2024, following his tenure as Acting Chief Financial Officer since October 27, 2023. "Marshall's decades of experience as a Chief Financial Officer for a variety of pharmaceutical and medical device companies makes him an obvious choice to appoint as a permanent Chief Financial Officer following his tenure in the acting role

DA-1726 Phase 1 IND Filing Expected by Year End 2023 Board Strengthened with Recent Appointment of Industry Veteran, James P. Tursi, M.D. Cash and Cash Equivalents of $25.8 Million, Expected to Fund the Company Into the Fourth Quarter of 2024, Through Multiple Potential Value Creating Milestones BOSTON, Nov. 13, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate strategic update. "During the third quarter, we continued to advance the clinical development of our two, next generation ca

BOSTON, Aug. 14, 2023  /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of current Board member, Hyung Heon ("H.H.") Kim, as the Company's Chief Executive Officer and President, effective immediately. Mr. Kim succeeds Joseph Hooker, who served as interim Chief Executive Officer and President since January 2023. Prior to his appointment as Chief Executive Officer and President, Mr. Kim served as the General Counsel and a Senior Vice President of Dong-A ST Co, Ltd. ("Dong-A"), currently the Company's largest stockholder and NeuroBo's partner with respect to its n

BOSTON, May 12, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of Mark A. Glickman to its Board of Directors, effective as of May 11, 2023. "Mark is a highly accomplished pharmaceutical industry executive with more than 30 years of industry experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors. "I am pleased to welcome Mark to the NeuroBo Board of Directors and look forward to his contributions as we pursue the clinical development of our two cardiometabolic assets; DA-1241, a novel G-Prot

Experienced Executive Brings Approximately 40 Years of Pharmaceutical, Clinical Development and Operational Experience BOSTON, Jan. 18, 2023 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President. Mr. Hooker's appointment follows Gil Price, M.D.'s decision to retire from his position as President and Chief Executive Officer of NeuroBo. NeuroBo's Board of Directors plans to initiate a candidate search with the assistance of a leading executive search firm to identify Dr. Price's permanent successor.

BOSTON, May 6, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment, effective April 30, 2022 of Matthew Bardin, PharmD, BCPS as Senior Vice President, Operations. Reporting directly to President and Chief Executive Officer, Gil Price, M.D., Dr. Bardin will be responsible for day to day operations, with a focus on clinical development. "Matthew is a highly experienced pharmaceutical professional who brings to NeuroBo an extensive track record of clinical drug development, medical affairs and oversight expertise in a number of therapeutic areas, most importantly within the area of infectious diseases and gast

BOSTON, March 15, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment, effective immediately, of Danamarie Belpulsi, M.D., to its Scientific Advisory Board. "Dr. Belpulsi brings to NeuroBo extensive expertise within a number of highly relevant areas including infectious diseases, cardiology and neurology, to name a few," stated Gil Price, M.D., President and Chief Executive Officer of NeuroBo. "Additionally, her deep experience in the area of clinical trial research and her strong relationships with key opinion leaders, will be important as we move programs through the clinic, going forward." "I am delight

BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee. "Gordon is a highly accomplished executive with more than 35 years of experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors. "I am pleased to welcome him to the NeuroBo Board of Directors and look forward to his contributions as we pursue our next phase of growth and development." "I am excited to join the NeuroBo Board of

4/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)

4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)